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ABSTRACT
Pop2: A Potential Regulator of Hmt1-Catalyzed
Arginine Methylation in Yeast

by

Celeste Excell, Master of Science
Utah State University, 2014

Major Professor: Dr. Joan M. Hevel
Department: Chemistry and Biochemistry

Protein arginine methylation is an important post-translational modification that is
vital in regulating various cellular processes such as gene transcription, cell signaling,
and RNA processing. Protein arginine methyltransferases (PRMTs) are responsible for
performing this important modification. PRMT1 (protein arginine methyltransferase 1)
and Hmt1 (hnRNP methyltransferase 1) are the predominant PRMTs in humans and
yeast, respectively. Despite growing momentum in this field, relatively little is understood
about PRMT regulation. Further work discovering how PRMTs are regulated will greatly
advance our understanding of diseases where PRMTs have been implicated, such as
heart disease, viral pathogenesis, and cancer.
It has been discovered that a human protein called hCaf1 (human Ccr4associated factor 1) is a regulator of PRMT1 with respect to certain substrates, and also
colocalizes with PRMT1. We present data that suggest the yeast homolog of hCaf1,
Pop2, may also perform a similar function on Hmt1. We provide data on the expression
and purification of a truncation of Pop2 from S. cerevisiae, including the temperature
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sensitivity of one construct of Pop2 and its susceptibility to precipitation. We also
demonstrated concentration-dependent inhibition of Hmt1-catalyzed methylation of
histone H4 by Pop2 in vitro. Yeast cell lysates also showed altered patterns of
methylation in the presence and absence of Pop2 in vivo. In an effort to understand the
mechanism employed by Pop2 to accomplish this regulatory function, pull-downs were
performed suggesting that Pop2 directly interacts with histone H4, a substrate of Hmt1.
Mutagenic studies with Pop2 suggested a region that may be responsible for this
interaction. Given these data, we hypothesized that Pop2 is able to inhibit the
methylation

of

histone

H4

via

a

substrate-sequestering

mechanism.

Further

experimentation will determine the precise interaction surfaces of Pop2 and substrate,
and continue to define the details of methylation inhibition by Pop2, including the scope
of its influence in the cell.
(73 pages)
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PUBLIC ABSTRACT
Pop2: A Potential Regulator of Hmt1-Catalyzed
Arginine Methylation in Yeast
Celeste Excell
Enzymes are ubiquitous within our cells, and perform a variety of essential
functions as they catalyze important biochemical reactions that allow us to develop,
grow, adapt, and live. Each enzyme has a unique function, but these functions often
need to be regulated. PRMTs (protein arginine methyltransferases) are one family of
enzymes that perform a specific type of modification (arginine methylation) on many
proteins (substrates), playing a role in numerous biological processes. PRMTs are so
widespread and vital to the cell that dysregulation of these enzymes has profound
detrimental effects, implicating PRMTs in several human diseases such as
cardiovascular disease and cancer. This emphasizes the urgency in understanding how
PRMTs are regulated. A human protein, hCaf1, was discovered to regulate the activity of
PRMT1, the predominant PRMT in humans, with respect to certain substrates. We
investigated the yeast homolog of hCaf1, Pop2, and hypothesized that it would perform
a similar function in yeast. This thesis presents both in vitro and in vivo data that confirm
the regulatory function of Pop2 on Hmt1, the yeast homolog of PRMT1. We delved into
the mechanism that Pop2 employs to accomplish this regulation. We demonstrated that
Pop2 unexpectedly interacts with a substrate of Hmt1, suggesting a substratesequestering mechanism. This and future research will contribute to the foundational
knowledge of PRMT regulation, allowing the development of specific PRMT regulators to
treat and prevent human diseases where PRMTs have been implicated.
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CHAPTER 1
INTRODUCTION
Overview
Communication is a vital component of our world, from international news down
to intracellular signals. The exchange of information on any level requires some kind of
language, a means for transmitting this necessary information. Just as nations have
written and spoken languages, and computers have binary and algorithms, cells have
languages all their own. From the smallest bacteria to a complex human being, cellular
communication is a requirement for life. Discovering how cells and cellular components
talk to each other has been an ongoing endeavor for decades.
The scientific community has gained an extensive understanding of many
aspects of cellular communication and signaling, including the expansion of the
proteome through post translational modifications (PTMs). PTMs are covalent
modifications of proteins that alter their function. Examples of these modifications
include phosphorylation, acetylation, methylation, ubiquitination, lipidation, glycosylation,
and many others. PTMs play a valuable role in regulating transcription and signal
transduction, altering protein interactions and localization, influencing enzymatic activity,
protein stability and folding, and many other cellular processes. Considering the
pervasiveness and importance of PTMs to so many aspects of cellular physiology, it is
crucial to gain as much knowledge of them as possible in order to better understand not
only how cells function, but also how cells malfunction. This information is then utilized in
developing prevention strategies and pharmaceuticals to treat those malfunctions that
cause human disease and illness.
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SAM-Dependent Methylation
One of the PTMs mentioned above is methylation, and it is the fourth most
common type of PTM based on putative methylation sites.1 Protein methylation can
occur on the C- or N-termini of polypeptides as well as on amino acid side chains,
typically arginine and lysine.2,3 These methylations are performed by a class of enzymes
called methyltransferases (MTases), which transfer a methyl group (-CH3) from a methyl
group donor to the substrate. MTases that rely on S-adenosyl-methionine (SAM, or
AdoMet) as the methyl group donor are referred to as SAM-dependent, or AdoMetdependent MTases.
SAM is a widespread substrate, perhaps second only to ATP, and participates in
a variety of reactions including decarboxylation and hydroxylation reactions, adenylyl
transfer, and even radical mechanism reactions.4,5 SAM also serves as a precursor to
numerous compounds.4,5 However, its predominant function is methyl group donation to
proteins, DNA, RNA, and numerous other substrates, such as those involved in arsenic
metabolism, and in the synthesis of plant sterols, methyl halides, methanethiol, and
other compounds.5–10 With a wide variety of substrate targets, versatile applications, and
favorable energetics (-17 kcal/mol), SAM makes an ideal methyl donor, although there
are others that are less common such as N5-methyltetrahydrofolate.11,12
Most SAM-dependent MTases contain a conserved SAM-binding domain, a
Rossman fold, or “AdoMet-dependent MTase fold,” despite a lack of sequence identity
among them.4,11,13 These binding domains place SAM in an in-line position to their
respective bound substrates so that the methyl group of SAM can be transferred to the
substrate via an SN2-type reaction mechanism, resulting in a stereochemical inversion of
the methyl group.14,15 The positive charge of the sulfonium group of SAM assists in
making the methyl group more susceptible to nucleophilic attack by the substrate. Once
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the methyl group is donated, the enzyme releases S-adenosyl-homocysteine, (SAH, or
AdoHcy) and the newly modified protein as products of the reaction (Figure 1-1).

Figure 1-1. Structures of SAM and SAH (A) S-adenosyl-L-methionine, abbreviated as
SAM, or AdoMet, and (B) S-adenosyl-L-homocysteine, abbreviated as SAH, or AdoHcy.

Arginine Methylation
As mentioned above, arginine is one of the most common amino acid residues to
be methylated. Arginine has several characteristics that make it unique among the
amino acids, such as the ability to participate in five different hydrogen bonds.16
Arginine’s interactions with DNA, RNA, and other proteins are made possible by its
ability to participate in ionic salt bridges, cation-π interactions, and Van der Waals
interactions.2
Arginine methylation is also a rather unique PTM, and two facts emphasize the
evolutionary significance of methylated arginines: they are only found in eukaryotes, and
each methylation event is very energetically expensive, requiring the utilization of 12
ATP.2,17,18 At such a high energetic cost, the cell must greatly value and rely on the PTM
of arginine methylation.
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Although a methyl group may seem small, its effects can have a significant
impact on protein-DNA, protein-RNA, and protein-protein interactions. A methyl group
does this by eliminating hydrogen bond potential, adding bulkiness and steric hindrance,
and increasing hydrophobic interactions with other residues such as tryptophan.2 In fact,
the interaction between dimethylated arginine and tryptophan is twice as strong as the
same interaction with an unmethylated arginine.19 The altered interactions are important
for a variety of functions: signal transduction, RNA splicing and processing, nuclear
export, DNA repair, chromatin organization, regulation of transcription, and many
others.2,3,16,17,20–25
Another distinctive feature of arginine is that it has multiple nitrogen atoms that
are capable of being methylated. This gives rise to the four different forms of methylated
arginine, the most prevalent of which is asymmetric dimethyl arginine (ADMA) (Figure 12).2,16 The other forms include symmetric dimethyl arginine (SDMA), and monomethyl
arginine (MMA). These modifications all occur on the terminal guanidino nitrogens of
arginine. However, the fourth form has the δ-nitrogen of the guanidino group
monomethylated, termed δ-MMA (not shown in the figure), and has only been reported
in yeast.2,26
Protein Arginine Methyltransferases (PRMTs)
The family of enzymes that is responsible for arginine methylation is the protein
arginine methyltransferase (PRMT) family. In mammals, there are 11 different PRMTs,
and they are categorized by the type of modified arginine they produce (Figure 1-2).
Type I PRMTs catalyze the reaction that produces MMA and ADMA, and these include
PRMTs 1, 2, 3, 4/CARM1, 6, and 8.26,27 Type II PRMTs produce MMA and SDMA, and
these include PRMT5, and possibly 9.16,26 Type III PRMTs are responsible for the
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production of solely MMA, and this category includes PRMT7.3 PRMT10 and 11 have
been identified by their homology with PRMT7 and 9, but their specific PRMT activity is
yet to be determined by experimental evidence.3,16,26,27

Figure 1-2. PRMT Methylation Products. Protein arginine substrates are modified to
form MMA, ADMA, and SDMA by type III, type I, and type II PRMTs, respectively.

In mammals, the predominant PRMT is PRMT1 which is responsible for about
85% of the arginine methylation that occurs.3,27 PRMT1 has seven isoforms, each of
which is altered in the N-terminal sequence.28 These isoforms are tissue-specific, and
vary in their substrate specificity and enzymatic activity. The prevalent balance and
expression of these isoforms has been implicated in several different human diseases,
including cancer.28
Structural Insights into PRMTs
Crystal structures of various PRMTs have been solved, which greatly contribute
to our current understanding of PRMTs and how they function.29–34 Throughout all of
these structures, the catalytic core of the PRMT enzymes is conserved. This catalytic
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core is comprised of a SAM-binding domain, a β-barrel domain, and a dimerization arm,
with the active site nestled in a deep pocket between the SAM-binding and β-barrel
domains. The active site also contains a strictly conserved hairpin called the “double E
loop,” where two catalytic glutamates reside. These studies also provide evidence that
homodimerization of PRMTs is required for SAM binding and catalytic activity.29–34
The structure of PRMT1 is of particular interest as it is the predominant PRMT in
mammals, and structural and enzymatic studies of its wild type and mutant forms have
unveiled many valuable pieces of information about its mechanistic and functional
characteristics.27,32,35,36 In order to gain a better understanding of this important
workhorse of the PRMT family, the yeast homolog of PRMT1 from Saccharomyces
cerevisiae (Hmt1/Rmt1) can also provide valuable insights into this enzyme in the
context of a more simple eukaryotic system, and will be the focus of this thesis.
Protein Arginine Methyltransferases in Yeast
The predominant PRMT in yeast (S. cerevisiae) is Hmt1/Rmt1. As the yeast
homolog of PRMT1, Hmt1 is also a type I PRMT, catalyzing the formation of MMA and
ADMA. Hmt1 is responsible for 89% of the ADMA and 66% of the MMA formed in yeast
in vivo.2
The crystal structure of Hmt1 has been solved, and shows many similarities to
PRMT1.33 Hmt1 forms a homodimer that is essential for activity, mediated by its
dimerization arm, or “antenna.” This antenna is a small, two helix bundle, and when
mutated to a series of alanines, Hmt1 loses its ability to dimerize, as well as its catalytic
activity.33 Gel filtration experiments show that both PRMT1 and Hmt1 form a hexamer in
solution, and both crystallize as a trimer of dimers, although the functional role of the
hexamer is unclear.32,33
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Other PRMTs in yeast include Rmt2, Hsl7 (the yeast homolog of PRMT5), and
Sfm1.2 Rmt2 is a unique PRMT in that it catalyzes the addition of a methyl group to the
δ-nitrogen of arginine instead of one of the ω-nitrogens, making it a type IV PRMT.37
Although this type of methylation is present in other lower fungal species, it is not
conserved in higher eukaryotes. One of Rmt2’s known substrates is a ribosomal protein
L12, and Rmt2 also associates with specific nucleoporins, but details of its roles in the
cell remain unclear.2,37
Hsl7, like PRMT5, is a type II PRMT and catalyzes the formation of MMA and
SDMA.2,18,38 Although in vivo substrates of this enzyme are unclear, it is known to be
important in cell cycle regulation, and is also important for cell survival under
hyperosmotic stress.2
Sfm1 is the fourth and last of the currently known PRMTs in yeast. It has been
tentatively classified as a type III PRMT since it has only been shown to monomethylate
a small ribosomal protein, Rps3.39 The specific functional role of this modification has yet
to be elucidated. In addition to the four PRMTs currently documented in yeast, there is
still PRMT activity that is unaccounted for, suggesting that there are other PRMTs that
have yet to be characterized in this species.2
Despite the prevalence of other PRMTs in yeast, our focus is on Hmt1, the yeast
homolog of PRMT1. This project is mainly concerned with discovering how Hmt1 is
regulated in hopes that our findings can be used in studying PRMT1 and uncovering
potential avenues for treating and preventing diseases related to PRMT dysregulation.
The studies in this thesis involve a yeast protein, Pop2, and its role as a potential
regulator of Hmt1.
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Substrates and Roles of Protein Arginine Methylation
PRMTs typically methylate arginines located in glycine-arginine-rich (GAR)
motifs, usually in the form of RGG sequences, although there are exceptions to this rule.
For example, PRMT1 performs methylations in RXR sequences, and in some RGX and
RXG sequences.2,16,26
RNA binding proteins (RBPs) represent a major substrate of PRMTs as a result
of most of them harboring GAR motifs, and many of them have been identified as being
arginine methylated.22 Two of these RBPs in yeast, Npl3 and Nab2, shuttle RNA from
the nucleus to the cytoplasm, and this function has been shown to be methylation
dependent.2,40 In mammals, the methylation status of other RBPs, such as Sam68 and
RNA helicase A which are methylated by PRMT1, determines their subcellular
localization and contributes to their function and regulation.20,41
As mentioned earlier, methylated arginines play important roles in a variety of
cellular functions in addition to RNA processing. Ribosomal proteins have also been
identified as substrates of arginine methylation, and this PTM is evolutionarily
conserved.2 As a modification that is growth-condition dependent in yeast, and cell
cycle-dependent in HeLa cells, it appears that ribosomal arginine methylation plays an
important role in translational regulation.42,43
Signal transduction is another area where arginine methylation has been shown
to play an important role by strengthening or blocking certain interactions. 22 A few
examples of signaling pathways that utilize arginine methylation include T-cell,
interferon, cytokine, and nerve growth factor signaling. 22,44 Recently, a study has shown
that the Smad signaling cascade also involves PRMT1 activity in order to transmit the
signal from the membrane bound receptors that bind BMPs (bone morphogenetic
proteins) into the cell, which influences levels of gene transcription.45
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Some substrates of PRMTs are involved in DNA damage checkpoint control and
repair. MRE11 is a substrate of PRMT1 within its GAR domain, and the presence of the
ADMA modification regulates the exonuclease activity of MRE11.46 The p53 protein is
methylated by PRMT5 in response to DNA damage, which influences the regulation of
subsequent cell cycle arrest.21 These results among others illustrate the valuable role of
arginine methylation in regulating the cell’s response to DNA damage and repair.
One of the more well-studied areas of arginine methylation is the methylation of
histones, and the subsequent effects this modification has on transcriptional regulation.
To date, there are five PRMTs in mammalian systems that are known to methylate
histones.23 Histone sites H3R17 and H3R26 are asymmetrically dimethylated by
PRMT4, and PRMT6 also asymmetrically dimethylates H3R2.23 PRMTs 1, 6, and 8
modify H4R3 and H2AR3, and these modifications are associated with actively
transcribed promoters.47–49 PRMT5 symmetrically dimethylates H4R3, H2AR3, and
H3R8.50,51 These modifications by PRMT5 are linked to transcriptional repression and
gene silencing.50,51 Since both PRMT1 and PRMT5 methylate H4R3 in different ways
(ADMA and SDMA, respectively), it is reasonable that the two enzymes produce
antagonistic effects; one (ADMA) turns transcription of a gene on while the other
(SDMA) turns it off. Conversely in yeast, Hmt1-catalyzed asymmetric dimethylation of
H4R3 is shown to repress transcription and is involved in silent chromatin
formation.23,47,48,52 Methylation of histone H4R3 by Hmt1 is a primary focus of this project,
and our main endeavor has been discovering how methylation of this particular substrate
can be regulated by Pop2, another yeast protein.
Another interesting aspect of histone arginine methylation is its interactions and
interplay with other histone modifications, such as acetylation and lysine methylation.
Hmt1 has been shown to preferentially bind and methylate acetylated histones.53 This
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theme of acetylation and methylation cooperatively interacting seems to be conserved in
mammals as well. When PRMT1 was knocked down in an erythroid cell line, there was a
loss of acetylation on both histones H3 and H4, as well as an increase in lysine
methylation.54 Lysine methylation is a well-characterized PTM of histones, and is
hypothesized to crosstalk with arginine methylation sites in the form of “arginine/lysinemethyl/methyl switches.”23,55 In these switches, a methylated arginine or lysine
influences the subsequent modification of another adjacent arginine or lysine. Although
some details remain elusive of how arginine methylation of histones functions in the
context of epigenetics, it is clear that it plays an important role in regulating transcription
as part of the histone code.23,55
PRMTs can also influence transcriptional regulation through methylation of nonhistone proteins.2 In mammals, co-activators of transcription can be methylated, which
leads to the modification of histones and subsequently altered transcription levels.3,22 A
more direct method documented in mammals is methylation of transcription factors that
can activate gene transcription.3,22 In yeast, Hmt1 can affect transcription elongation and
termination by methylating anti-terminator and terminator proteins such as Npl3 and
Hrp1, respectively.40,56
These findings among many others make it clear that from yeast to humans,
PRMTs carry critical responsibility in regulating transcription for proper cell functioning.
Discovering how PRMTs are regulated in the context of transcriptional regulation and
other cellular processes is critical for future therapeutic and pharmaceutical applications.
We are particularly interested in the methylation of histone H4 in yeast, as it is one of the
more prominent substrates of Hmt1. This project aims to discover how Hmt1-catalyzed
methylation of histone H4 is regulated, as this particular PTM can have very far-reaching
and widespread consequences in terms of transcriptional regulation.
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PRMT Regulation
Compared to the rest of the collective knowledge of PRMTs, less is known about
their regulation. Arginine methylation is considered to be a mostly irreversible PTM,
since no true demethylases have been identified thus far. Considering the somewhat
permanent nature of arginine methylation in combination with the high energetic cost of
each methylation event (12 ATP), it must be extremely important to the cell to tightly
regulate this PTM.17,18 Currently known methods of regulation include PRMT-binding
proteins and small molecules, oligimerization, deimination and demethylimination,
adjacent PTMs of substrates, and direct modification of PRMTs with PTMs.2,3,24,38,57–60
These methods of regulation can activate, enhance, and inhibit enzymatic activity, or
alter substrate specificity.2 This project explores a novel function of a yeast protein,
Pop2, as a regulator of Hmt1-catalyzed arginine methylation. We are interested in the
ability of Pop2 to modify the activity of Hmt1 toward certain substrates such as histone
H4. Before that is discussed, however, a brief summary of other regulatory methods of
PRMTs is provided below.
Protein-protein interactions utilized in PRMT regulation are known to occur with
multiple PRMTs, both mammalian and yeast. The enzymatic activity of PRMT1 is
enhanced when interacting with PRMT2, affecting its Km and Vmax values.61 Activity of
PRMT1 is also increased when bound to BTG1 or BTG2 proteins with respect to certain
substrates.62 Human Ccr4-associated factor 1 (hCaf1), a BTG1-binding protein, has
been shown to co-localize with PRMT1 in vivo, and regulate the methylation of histone
H4 and Sam68 substrates.57 hCaf1 is the human homolog of the yeast Pop2 protein, and
its relationship with PRMT1 will be discussed in more detail later on.
Another example of protein interaction regulation is PRMT4/CARM1 and its
ability to methylate nucleosomal histone H3 when it is part of the NUMAC complex
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(nucleosomal methylation activation complex), as opposed to preferentially methylating
free histone H3 when not associated with NUMAC.63 One domain of the DAL-1/4.1B
tumor suppressor protein associates with PRMT3, and inhibits methylation of one of its
substrates.64 The substrate specificity of PRMT5 is modified by cooperator of PRMT5
(COPR5). When COPR5 bound to PRMT5, histone H4 (Arg 3) was methylated
preferentially over histone H3 (Arg 8), both of which are substrates of PRMT5. 65
Although these are just a few examples, protein-protein interactions are a widespread
and well-documented method of regulating PRMTs.
Oligimerization of PRMTs is another method of regulating arginine methylation.
Homodimerization and multimerization have been shown to be essential for some of the
PRMTs including Hmt1, PRMTs 1, 4, and 5.33,66,67 As a result, anything that disrupts
these oligmerization interactions contributes to reduced or no enzymatic activity of the
PRMT. A cell could use post translational modifications, oxidation/reduction, or other
means to regulate PRMT oligimerization.67,68
Demethylation could potentially be another method of regulating arginine
methylation, though no true arginine demethylases have been identified as of yet. The
discovery of lysine demethylases and their importance in regulating histone lysine
methylation were critical advancements in our understanding of the reversibility of
methylation.69 The existence of lysine demethylases and therefore lysine demethylation
implies that arginine methylation reversal may be a viable means of PRMT regulation
despite the lack of a known arginine demethylase enzyme.70 Several years ago, a study
reported that a Jumonji-domain containing protein, JMJD6, displayed histone
demethylase activity.71 However, other laboratories were unable to replicate these
results, and characterized JMJD6 as a lysine hydroxylase enzyme.72,73 Further work is
needed to continue searching for a true arginine demethylase in humans. As of now, no
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arginine demethylase has been reported in yeast.2 Two of the currently known lysine
demethylases, Jdh1 and Jdh2, are conserved in S. cerevisiae, suggesting there could be
an analogous undiscovered arginine demethylase in yeast.2,74,75
Somewhat similar to demethylation, deimination is a PTM that prevents an
arginine methyl modification of a substrate by converting an arginine residue to citrulline.
The enzymes that catalyze this reaction are peptide arginine deiminases (PADs), and
the core histones are one of the major groups of proteins that are deiminated.18,23 A
substrate of PRMT4, p300, has also been shown to be deiminated by PAD4.24
Experimental evidence is contradictory whether PADs can perform demethylimination
reactions (converting MMA, SDMA, or ADMA into citrulline). 76–78 At best, PADs may do
so very inefficiently in vitro.58 In addition, the deimination reaction could be an
irreversible modification, as there has not yet been an enzyme identified that can convert
citrulline back into an arginine residue.58 Although PADs are not true “demethylases,”
they are prevalent in mammalian cells and may play a vital role in PRMT regulation in
mammals. However, there has not yet been any evidence of demethylimination or
deimination in yeast.2
PTMs directly on PRMTs are another method of regulating their enzymatic
activity. Some PRMTs, such as PRMT6 and 8, are automethylated, but the physiological
function of this PTM is still unclear.3,79 PRMT4 has been shown to be phosphorylated,
which reduces its enzymatic activity by disrupting its ability to dimerize.67 Hsl7 has also
been shown to be phosphorylated, although this modification in yeast did not seem to
affect its enzymatic activity.80 Recently, Hmt1 was shown to be phosphorylated on serine
9, and this was hypothesized to be an essential PTM for Hmt1 oligimerization and
activity.59 The Hmt1 S9E mutant (a phosphorylation mimic) was shown to be
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constitutively active, even under starvation and rapamycin-treated conditions, whereas
wild type Hmt1 was not active under these conditions.59
PTMs on substrates, either adjacent to or directly on the arginine in question, can
also regulate PRMTs. One example of adjacent PTMs was mentioned earlier with
arginine/lysine methyl/methyl switches.23,55 A recent study with PRMT1 knockdown
suggested that different PRMTs may regulate each other by using one form of
methylated arginine to preclude the formation of another.81 When PRMT1 (a type I
PRMT) was knocked down, this resulted not only in reduction of ADMA, but also in an
increase of SDMA and MMA (catalyzed by type II and III PRMTs, respectively). This
effect was referred to as “substrate scavenging,” and suggests that the ADMA
modification catalyzed by PRMT1 may be a form of regulation by preventing other
PRMTs from forming MMA or SDMA on those same substrates.81
Perhaps the most drug-target-oriented method of PRMT regulation is that done
by small molecules. Specific activation or inhibition of PRMTs could be of great
pharmaceutical value in treating a variety of diseases that show dysregulated PRMT
activity.38 Studies have found small molecules that enhance the enzymatic activity of
PRMT4 toward both histone and non-histone substrates.60 However, specificity of PRMT
modulators as well as other challenges make this endeavor very difficult.38 One of the
studies utilizing small molecules has shown inhibition of PRMTs specific enough to not
affect lysine methyltransferases, although the mechanism is unknown. 60 Others have
modeled potential inhibitors that employ a SAM/SAH analog, substrate analog, or both,
which could bind in the active site of specific PRMTs and selectively inhibit their
activity.38 Further experimentation will be needed for drug-inducible regulation that is
either PRMT-specific or substrate-specific to become possible. This is an important
aspect of PRMT regulation as inhibition of all or multiple PRMTs could result in serious
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and harmful side-effects. Considering how widespread PRMTs are, specificity of
regulation is critical.
There are many ways that the cell is able to monitor and regulate the activity of
PRMTs, both discovered and undiscovered. Suffice it to say that despite the above
described regulatory mechanisms that are currently understood, there is still much
ground to cover in fully comprehending this area of PTMs. This project seeks to advance
our understanding of PRMT regulation through experiments with Hmt1 and Pop2, a
potential new regulator of arginine methylation in yeast.
Clinical Significance
PRMTs have been implicated in a wide range of human diseases, including
cancer, cardiovascular disease, spinal muscular atrophy, and viral pathogenesis.3,22
Given that arginine methylation is a relatively young field compared to some PTMs, our
current understanding of the function of PRMTs in human disease is relatively limited.
However, this field is quickly expanding as we begin to realize the pervasive influence of
PRMTs in the development and progression of cellular malfunction and disease.
Several PRMTs have been implicated or reported as being dysregulated in many
types of cancers. Some of these include mantle cell lymphoma, lymphoid, bladder, and
lung cancers, as well as hormone-dependent cancers such as prostate and breast
cancers.28,50,82–84 PRMTs 1 and 4 were shown to be overexpressed in many breast
cancer cell lines, in addition to overall increased ADMA levels.28 PRMTs 1 and 6 were
upregulated in a variety of cancers.84 PRMT4 was also overexpressed in human prostate
carcinomas, and contributed to androgen independence.28,82 PRMT4’s role in prostate
cancer progression marks it as a prime potential drug target in treating these types of
cancer.83
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A tumor suppressor protein, p53, is known to be regulated by two PRMTs:
PRMT5 methylates p53, determining whether the cell repairs damaged DNA or
undergoes apoptosis; and PRMT6 negatively regulates the transcriptional levels of
p53.21,85 Studies show that knockdown of these and other PRMTs, such as PRMT5,
reduces the proliferation of cancer cells.50 This suggests that inhibiting PRMTs could be
a potentially powerful drug-target by altering epigenetic modifications of aberrant PRMTs
and increasing cancer cells’ sensitivity to chemotherapeutics.38,50
Cardiovascular diseases (CVD) are another area of clinical significance related to
PRMTs because of CVDs strong link established with ADMA. Free ADMA is generated
from the proteolysis of type I PRMT substrates, and functions as an endogenous
inhibitor of nitric oxide synthase (NOS), an enzyme located in blood vessel endothelium
responsible for generating nitric oxide (NO) from L-arginine. NO is a vasoactive mediator
that contributes to vasodilation and other anti-atherosclerotic functions.86 When plasma
ADMA levels rise and the ratio of L-arginine to ADMA falls, cardiovascular diseases such
as hypertension, stroke, congestive heart failure, coronary artery disease, and diabetes
are more likely to result.86
An enzyme that helps to alleviate the inhibitory effects of ADMA is
dimethylarginine dimethylaminehydrolase 1 (DDAH1), which is responsible for degrading
free ADMA.86–88 Inhibition or diminished expression of this enzyme can result in tipping
the balance toward more ADMA. This imbalance has been associated with dysfunctional
endothelium in the above mentioned disease states, and is hypothesized to be the
cause of ADMA-mediated NOS inhibition.87 Indeed, DDAH1 knockout mice exhibited
accumulation of plasma ADMA and MMA, a decrease in the L-arginine to ADMA ratio,
and about 20 mmHg increase in blood pressure compared to wild type mice. 86
Additionally, other studies have administered ADMA to guinea pigs and rats, which also
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resulted in increased plasma ADMA levels coupled with increased blood pressure.89
Similar studies have been conducted in humans, resulting in overall diminished NO
levels and impaired endothelial function.89
Interestingly, increased ADMA levels have been shown to alter gene expression
in endothelial cells.90 When human coronary artery endothelial cells were treated with
ADMA, genetic expression of bone morphogenetic proteins, ribosomal proteins, PRMT3,
and other genes were markedly increased.90 It appears that excess ADMA can alter
endothelial function both dependently and independently of NOS. The effects of excess
ADMA further highlight the importance of understanding how PRMTs are regulated, how
they become dysregulated, and what can be done to prevent or reverse these negative
physiological consequences.
A third area of clinical significance for PRMTs is spinal muscular atrophy (SMA).
SMA is an autosomal recessive genetic disorder resulting from deletions in the survival
motor neuron (SMN) gene.91 SMN proteins contain Tudor domains, which are known to
interact with other proteins in a methylation-dependent manner.92–94 These SMNinteracting proteins include substrates of PRMTs 4 and 5, making both ADMA and
SDMA important post-translational modifications linked with the progression of SMA.
Some of these same SDMA-modified protein substrates have also been linked with
systemic lupus erythematosus (SLE).95 Understanding how these PRMTs are regulated
and being able to artificially manipulate their activity could provide methods of alleviating
symptoms and increasing quality of life for patients with SMA and SLE.
A fourth and final clinically significant aspect of PRMTs discussed here is viral
pathogenesis. PRMTs 1, 5, and 6 and their methylated substrates have been linked to
the virulence of HIV, Epstein-Barr virus (EBV), and hepatitis delta virus (HDV).96–98 In
HIV, PRMT6 methylation of a Tat protein resulted in a negative regulatory effect by
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diminishing Tat’s affinity for RNA and other proteins.96 This suggests that activation of
PRMT6 could help decrease the virulence of HIV. One of the very first proteins made by
the EBV upon infection (EBNA2) is methylated by PRMT5.97 This methylation is required
for protein-protein interactions that allow B cell transformation and progression of
infection.97 In HDV, the methylation of a small hepatitis delta antigen by PRMT1 is
essential for the replication of RNA, while inhibiting this methylation event blocks viral
replication.98 These findings suggest that specifically blocking or enhancing certain
methylation events could help treat or slow the progression of these viral infections.
These examples emphasize the urgency that exists in learning more about
PRMTs and their influence in disease. Considering the widespread and important role
that PRMTs play in healthy and unhealthy cells, it becomes even more important to
discover how PRMTs are regulated, and how we can exploit their regulatory
mechanisms in treating and managing the above described human diseases. Working
within a yeast model allows a more tractable approach while still providing valuable
insight into the regulation of the PRMT family. This thesis focuses on the yeast protein
Pop2, and it’s potential role as a regulator of the yeast homolog of PRMT1, Hmt1.
Pop2: A Potential Regulator of PRMTs
hCaf1 was discussed earlier as a novel regulator of PRMT1 activity with respect
to certain substrates.57 Although hCaf1’s regulatory mechanism is still unclear, this
finding provided a starting point to explore this phenomenon in the eukaryotic yeast
model, Saccharomyces cerevisiae. Pop2, similar to its human homolog hCaf1, is part of
the Ccr4-Not complex, and possesses deadenylase activity both with its complex and
alone.99,100 Although Pop2 is capable of deadenylation, the main deadenylase of the
Ccr4-Not complex is Ccr4.101 Pop2 does, however, play a unique regulatory role by
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interacting with other proteins such as Puf5 in recruiting the rest of the complex to
mRNAs.102
The Ccr4-Not complex regulates gene products almost every step of the way
from transcription and mRNA nuclear surveillance to nuclear export, translational quality
control, deadenylation and mRNA decay, and thus resides in both the nucleus and the
cytoplasm.101,103–105 Knocking out each of the nine subunits of the Ccr4-Not complex one
at a time resulted in altered mRNA transcript levels for many genes, emphasizing this
complex’s role as a general regulator of transcription and mRNA decay.106 The Ccr4-Not
complex has also been shown to associate with the proteasome, and together, regulate
lysine methylation modifications on histones in a ubiquitin-dependent manner.107 If the
Ccr4-Not complex regulates lysine methylation, then it is feasible that the complex or
one of its components could also regulate arginine methylation. Indeed, this was shown
in the PRMT1 and hCaf1 study mentioned earlier. In yeast, several components of the
Ccr4-Not complex (including Pop2) were demonstrated to interact with Hmt1 and several
of Hmt1’s substrates.105 Considering the relative novelty of these findings, very few
details about the interactions and regulatory mechanisms of hCaf1 and Pop2 (in addition
to the rest of the Ccr4-Not complex) and their roles in arginine methylation have been
elucidated. The studies presented in this thesis begin to uncover the details in a yeast
model system of Hmt1 regulation by Pop2 in order to better understand how hCaf1
regulates PRMT1 in humans and therefore advance our understanding of PRMT
regulation.
Summary and Hypothesis
Protein arginine methylation is a vital and widespread PTM conserved throughout
eukaryotic systems. PRMTs and their substrates play a significant role in a variety of
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biological processes and many human diseases, including cardiovascular disease and
cancer. Understanding how PRMTs are regulated is an important step in utilizing
medicinal tools in treating and curing these diseases, but there is still a great deal of
progress that needs to be made before we can fully unlock the potential of modulating
PRMT activity. Recent evidence suggests that hCaf1 in humans, and Pop2 in yeast, may
help illuminate some of the regulatory mechanisms of PRMT1 and Hmt1, respectively. In
order to contribute to this ever-growing and significant area of research, this thesis will
provide part of the foundation needed to understand Hmt1 regulation by Pop2. Chapter 2
describes the optimized methods used to express and purify the yeast Pop2 protein.
Chapter 3 presents data that corroborates and expounds upon the homologous function
of hCaf1/Pop2 arginine methylation regulation and proposes a regulatory mechanism
based on novel protein-protein interactions. These studies, combined with future
research, will continue to expand our knowledge of the methylproteome and its
regulatory mechanisms, ultimately providing the basis for the future treatment and
prevention of many prominent human diseases.
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CHAPTER 2
EXPRESSION AND PURIFICATION OF POP2 PROTEIN
Introduction
Protein arginine methylation is an important post-translational modification (PTM)
that is vital in regulating various cellular processes such as gene transcription, cell
signaling, and RNA processing.1–5 PRMTs (protein arginine methyltransferases) are
enzymes that perform this modification. This family of enzymes utilizes a methyl donor
called S-adenosyl-L-methionine, abbreviated as SAM or AdoMet. The methyl group is
transferred from SAM to a terminal guanidino nitrogen on a protein arginine residue to
form MMA (monomethyl arginine). The substrate can then be further methylated to form
ADMA (asymmetric dimethyl arginine), which is catalyzed by type I PRMTs, or SDMA
(symmetric dimethyl arginine), which is catalyzed by type II PRMTs. A PRMT that stops
at the production of only MMA is considered a type III PRMT. 5,6 PRMT1 is the
predominant arginine methyltransferase in mammals, and catalyzes the formation of
ADMA, making it a type I PRMT.7
The study of PRMTs has gained momentum in recent years as their roles in
human diseases have become more apparent. In fact, PRMTs have been implicated in
cardiovascular disease, spinal muscular atrophy, viral pathogenesis, and cancer.4,5 As
such, PRMTs are becoming a more prominent target for the development of
pharmaceuticals to help treat or even cure the human diseases that are related to this
PTM.8 However, before we can manipulate or alter the activity of malfunctioning or
dysregulated PRMTs, there is much that needs to be discovered about how arginine
methylation is regulated in the cell. Despite the structural, kinetic, and catalytic
characterization of many of the PRMTs, relatively little is known about their regulation.
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Since no true arginine demethylases have been discovered, the regulation of this
somewhat permanent PTM becomes even more crucial to the cell. The currently known
methods of PRMT regulation include direct modification of PRMTs with PTMs,
oligimerization, deimination, adjacent PTMs of substrates, and PRMT-binding proteins
and small molecules.1,5,8–13 Of particular interest to us is the regulation of arginine
methylation via protein-protein interactions.
A certain human protein called hCaf1 was discovered to be a novel regulator of
PRMT1 with respect to certain substrates.9 Here, preliminary data suggest that the yeast
homolog of hCaf1, Pop2, may also perform a similar function on Hmt1. However, in
order to explore this novel regulator of Hmt1, the expression and purification conditions
needed to be optimized. The final construct that expressed and purified most
successfully was a truncation (Δ1-146) of Pop2, similar to the one used to solve the
crystal structure of Pop2.14 This construct also included a TEV (tobacco etch virus)
cleavable N-terminal polyhistidine tag (His-tag), and the protocols for purifying this
protein required slight but critical variations to standard purification methods.
Materials and Methods
Materials – QIAprep Spin Miniprep kit was purchased from Qiagen. Nickel resin
was purchased from GE Healthcare. SAM was purchased from Sigma. [3H]-SAM was
purchased from Perkin Elmer, and had a specific activity of 83.1 Ci/mmol. Histone H4
protein was purchased from New England Biolabs. R3 peptide is a short peptide
substrate commonly used for arginine methylation and has the following sequence:
GGRGGFGGRGGFGGRGGFGG. ZipTips®C18 pipette tips were purchased from
Millipore.
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Molecular Cloning – The Pop2 gene (accession number P39008) was PCR
amplified from S. cerevisiae cDNA using primers with NdeI and BamH1 restriction sites.
Full length Pop2 (433 aa) was inserted into a pET28b(+) vector with an N-terminal Histag. The truncated (Δ1-146) Pop2 was similarly PCR amplified and inserted into a
modified pET28b(+) vector that also contained a TEV-cleavage site between the His-tag
and the protein sequence. Additional vectors included a pDR177-Strep(II) expression
vector, based on a pET15b vector, as well as a pDB-GST PSI vector. All plasmids were
transformed into E. coli DH5α cells, grown overnight in 2XYT growth media at 37°C, and
purified using a QIAprep Spin Miniprep Kit. All plasmids were sent for sequencing to
verify correct sequence, reading frame, etc.
Recombinant Protein Expression – The plasmids with their respective Pop2
constructs were transformed into E. coli BL21 codon plus (DE3) cells in the presence of
appropriate antibiotics. Cells were grown in 2XYT media at 37°C until OD600 reached
0.6-0.8, followed by induction with 0.5mM IPTG. Induced cell growth continued at room
temperature for 24 hours. Cells were harvested via centrifugation and stored at -80°C
until used for purification of Pop2.
Protein Purification of Full Length Pop2 and Truncated (Δ1-146) Pop2 – Cell
pellets were resuspended in three times cell volume lysis buffer (50 mM phosphate, 100
mM NaCl, 20 mM imidazole, 5 mM MgCl2, 10 μg/mL RNase A, 10 mM βmercaptoethanol, pH=7.5). Cells were lysed using sonication, and cell debris was
pelleted using centrifugation. Clarified supernatants were applied to equilibrated nickel
resin in a 5:1 cell mass: resin ratio and allowed to incubate for 2 hours at 4°C. Resin was
washed eight times with ten column volumes of wash buffer (50 mM phosphate, 100 mM
NaCl, 20 mM imidazole, 5 mM MgCl2, pH=7.5), followed by six elutions with two column
volumes of elution buffer (50 mM phosphate, 100 mM NaCl, 250 mM imidazole, 5 mM
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MgCl2, pH=7.5). Elutions were pooled and filtered, and imidazole was eliminated by two
rounds of dialysis (two liters each of 50 mM phosphate, 100 mM NaCl, 5 mM MgCl2,
10% glycerol, 10 mM β-mercaptoethanol, pH=7.5). At this point, full length Pop2 was
beaded in liquid nitrogen and stored at -80°C. Truncated (Δ1-146) Pop2 was incubated
overnight to TEV cleave the histidine tag at 16°C. Protein was then put back over nickel
resin to bind TEV, incubated at 16°C, and Pop2 (Δ1-146) was collected in the flow
through. Purified protein was then beaded in liquid nitrogen and stored at -80°C.
Enzyme Assays – Reactions were performed in a 30°C water bath with various
concentrations of Pop2, 100 nM Hmt1 enzyme, 10 nM MTAN, 0.38 μM BSA, and 2 μM
SAM (1 μM cold SAM and 1 μM [3H]-SAM), in 50 mM phosphate buffer. Substrates were
either 0.5 μM histone H4 protein substrate, or 200 μM R3 peptide. Time points were
taken and quenched in 6 M guanidinium hydrochloride. Samples were processed using
ZipTips®C18, which separated unreacted [3H]-SAM from radioactively labeled product.
Processed samples were analyzed using a scintillation counter to quantify the amount of
methylation.
Results and Discussion
The first construct of Pop2 from S. cerevisiae that was attempted was a full
length His-tagged Pop2 construct. Despite multiple attempts with various growth
conditions and cell lines, Pop2 expression was considerably low. In addition, there were
two persistent contaminants (approximately 60 and 75 kDa) that were very difficult to
eliminate (Figure 2-1). Despite the poor expression levels and less than ideal purity of
Pop2, preliminary assays were performed to see if Pop2 had any regulatory effect on the
methylation of histone H4 protein substrate. Hmt1 reactions using [3H]-SAM were used
to measure the amount of methylation in the presence and absence of Pop2 (Figure 2-
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2). These preliminary results suggested that Pop2 does inhibit the methylation of histone
H4 protein by Hmt1. This prompted us to move forward in optimizing the expression and
purification of Pop2 for further assays as well as other experiments for better
understanding the interactions and inhibitory mechanism of Pop2.

Figure 2-1. Nickel resin purification of full-length His-tagged Pop2 protein. Pel =
pellet. Sup = supernatant. FT = resin flow through following incubation. Pop2 is outlined
in black box.

Figure 2-2. Preliminary Hmt1 enzyme assay showing methylation inhibition by
Pop2. Reactions were performed with histone H4 protein substrate in the presence (○)
and absence (■) of full length His-tagged Pop2 protein. No substrate present was used
as a baseline(●).
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Pop2 was inserted into other vectors in an attempt to improve total protein yield
and purity of final product. These included Streptavadin-tagged Pop2, and GST-TEVPop2 constructs. Streptavadin-Pop2 was unsuccessful because of such poor
expression, as well as the persistence of the same two impurities from the first construct
(Figure 2-3). Additionally, a buffer condition that would TEV cleave the Streptavadin tag
could not be determined. As a result, this construct was abandoned in an attempt to find
a construct of Pop2 with better expression and purification results.

Figure 2-3. Streptavadin resin purification of full-length Strep-TEV-Pop2 construct.
Pop2 protein is outlined in black box. P = pellet. S = supernatant. FT = flow through. W =
washes.
The next construct attempted was a TEV-cleavable GST-tagged full-length Pop2.
The GST-TEV-Pop2 construct expression was slightly better, but ultimately did not work
because a condition to TEV-cleave the GST tag could not be identified. Multiple buffers
and conditions were attempted with TEV, without success. Notwithstanding this,
inhibition assays similar to the ones described for the full length Pop2 were performed
with the GST-tagged Pop2 to see if the uncleaved protein would still show signs of
methylation inhibition. However, there was no apparent inhibition of histone H4
methylation, making this uncleaved construct unviable for future experiments. We
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hypothesized that the GST tag was obstructing an essential part of Pop2 that interfered
with its ability to regulate methylation. Similar to the Strep-Pop2 construct, this construct
was also abandoned and the search continued for an expressible, TEV-cleavable Pop2
protein that maintained its inhibitory effect on substrate methylation by Hmt1.
The last Pop2 construct attempted left out the first 146 amino acids from the Nterminus of the protein sequence, thus creating a similar construct to that used to solve
the crystal structure of Pop2.14 In addition to matching the crystal structure construct,
another reason for choosing this truncation was its sequence conservation with hCaf1.
The N-terminus of Pop2 does not align with hCaf1; sequence and structural alignments
with these two proteins are in the RNase domain, which begins at residue 147 for
Pop2.14
The Pop2 (Δ1-146) truncation was inserted into a modified pET28b(+) vector that
included a His-tag followed by a TEV protease cleavage site. Expression of the protein
was greatly increased for this construct, and the purity was also markedly improved
(Figure 2-4 A). Once Pop2 (Δ1-146) was purified, the next hurdle was TEV-cleaving the
His-tag. Surprisingly, the tag could be cleaved relatively easily under standard
conditions. However, severe precipitation would occur following TEV cleavage, resulting
in almost complete loss of any soluble protein.
All attempts to TEV-cleave the His-tag were done at 4°C in order to preserve the
integrity and catalytic activity of the proteins. However, closer inspection of the Pop2
crystal structure paper reported TEV cleavage at 16°C.14 When the TEV cleaving step
was performed at this higher temperature, the cleaved sample contained little to no
precipitation, resulting in much greater total protein yielded after the filtration step (Figure
2-4 B). Cleaved protein was put back over nickel resin to remove TEV protease enzyme
and other impurities that non-specifically bound to nickel resin. This step also needed to
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be carried out at 16°C to avoid protein precipitation. Cleaved Pop2 (Δ1-146) protein was
collected in the filtered unbound fraction, indicating that Pop2 (Δ1-146) was still soluble
and stable in solution.

Figure 2-4. Nickel resin purification of His-TEV-(Δ1-146) Pop2 and TEV cleavage.
(A) Nickel resin purification. P = pellet. S = supernatant. FT = flow through. Purified
Pop2 protein is outlined in black box. (B) His-TEV-(Δ1-146) Pop2 TEV cleavage and repurification using nickel resin. Cut = TEV cleaved protein. FT = nickel resin flow through
following incubation to bind TEV protease to resin. Filt. = filtered Pop2 protein. Purified
Pop2 protein is outlined in black box.

Conclusion
After numerous attempts to express and purify the Pop2 protein, the most
successful construct purified was a truncated construct consisting of amino acids 147433. Standard growth and His-tag purification procedures were utilized during
purification of Pop2 (Δ1-146). Interestingly, the TEV cleaving step and the subsequent
purification step to remove TEV required a 16°C incubation temperature to avoid severe
protein precipitation. A 16°C TEV-cleavage and repeated nickel purification to bind TEV
protease and other impurities was much more successful and yielded a much higher
amount of protein than the same procedure at 4°C. This suggests that the truncated (Δ1146) Pop2 construct is a temperature sensitive protein.
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Once the Pop2 (Δ1-146) protein expression and purification protocol was
optimized, a substantial amount (several milligrams) of the purified protein was able to
be stored for later use in experiments designed to further our understanding of Hmt1
methylation regulation. Chapter 3 provides evidence of inhibition of Hmt1 activity by the
truncated (Δ1-146) Pop2 construct, and explores the scope of regulation by full length
and truncated (Δ1-146) Pop2 on a variety of Hmt1 substrates. Chapter 3 also
investigates the mechanism that Pop2 (Δ1-146) utilizes to accomplish this regulation,
and analyzes the role of specific residues on the surface of Pop2 (Δ1-146) to probe a
potential binding interface responsible for this regulatory function.
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CHAPTER 3
REGULATION OF HMT1-CATALYZED METHYLATION BY POP2
Introduction
The expansion of the proteome relies on post translational modifications (PTMs)
to alter protein function. Arginine methylation is an important and widespread PTM
essential for a variety of cellular processes, including transcriptional regulation, RNA
processing, signal transduction, and others. The methylation of arginine residues relies
on a family of enzymes called PRMTs (protein arginine methyltransferases) to perform
this modification. PRMTs require a methyl group donor, S-adenosyl-L-methionine,
abbreviated as SAM or AdoMet. The methyl group is transferred from SAM to a terminal
guanidino nitrogen of an arginine residue in the protein substrate, forming S-adenosyl-Lhomocysteine (SAH, or AdoHcy) and methylated arginine as products. Given its unique
structure, arginine can be monomethylated (MMA), asymmetrically dimethylated
(ADMA), or symmetrically dimethylated (SDMA).
PRMTs are classified based on which form of methylated arginine they produce.
Type I PRMTs produce MMA and ADMA; type II PRMTs produce MMA and SDMA; type
III PRMTs produce solely MMA.1,2 Each of these modifications is unique and can
produce different biological effects. PRMTs have received greater attention in recent
years as these biological consequences have been implicated in human diseases such
as cardiovascular disease, cancer, viral pathogenesis, and spinal muscular atrophy.1–6
Given the growing evidence of the roles of PRMTs in disease, they are increasingly
becoming a target for therapeutic pharmaceuticals.7 However, there is much to learn
about PRMTs and how they are regulated before they can be specifically manipulated or
altered to treat such diseases.
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Compared to the global knowledge of PRMTs, relatively little is understood about
their regulation. We know of several mechanisms for regulating PRMTs, such as direct
modifications of PRMTs, adjacent PTMs on substrates, deimination, protein-protein
interactions, as well as others.1,8–12 However, this knowledge is just the beginning of
what is becoming a diverse and complex network of regulatory mechanisms for PRMTs.
PRMT1 is the predominant PRMT in mammals and catalyzes the formation of
MMA and ADMA, classifying it as type I.13 As the workhorse of the PRMT family, it is
consequently the most well understood PRMT with numerous studies investigating its
mechanism, structure, substrate specificity, and regulation. One such regulator, a human
protein called hCaf1 (human Ccr4-associated factor 1), was discovered to regulate the
methylation of certain substrates by PRMT1, specifically, Sam68 and histone H4.14
hCaf1 and PRMT1 were also shown to colocalize in vivo, suggesting they could be
interacting directly, or perhaps indirectly through one or more bridging molecules. 14 This
piqued our interest in discovering how PRMT1 could be regulated by this protein.
However, in order to take a closer look at how human PRMTs are regulated, it is often
good to start in a simpler model such as Saccharomyces cerevisiae, or baker’s yeast.
Hmt1 is the yeast homolog of PRMT1, making it a type I PRMT, and the
predominant methyltransferase in S. cerevisiae.12 The yeast homolog of hCaf1 is Pop2,
and these two proteins share many characteristics as they are both deadenylases in the
Ccr4-Not complex.15 Other encouraging findings included the discovered association of
Hmt1 and Pop2 in yeast, as well as the potential regulation of histone lysine methylation
by members of the Ccr4-Not complex.16,17 This led us to hypothesize that Pop2, like
hCaf1, may also regulate the methylation of certain Hmt1 substrates, such as histone H4
protein.
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Materials and Methods
Molecular Cloning – Pop constructs and vectors were obtained and utilized as
described in Chapter 2. The S. pombe plasmid used was a pET-30 Ek/LIC with a TEV
cleavage site between the His-tag and the protein sequence. It was generously sent to
us as a gift from Dr. Ditlev Broderson, Department of Molecular Biology and Genetics,
Aarhus University, Denmark. S. cerevisiae Pop2 (Δ1-146) variants (E260A, E263A, and
K267A) were created using appropriately designed primers and a QuikChange Lightning
Site Directed Mutagenesis Kit (Agilent Technologies). All plasmids were sent for
sequencing to verify correct mutations, sequence, and reading frame.
Protein Expression and Purification – Full-length and truncated (Δ1-146) Pop2
from S. cerevisiae were expressed and purified as described in Chapter 2. Pop2 from S.
pombe was expressed using BL21 Ni-Co (DE3) cells in ZY media, and protein
expression was induced using auto-induction. Cell pellet was resuspended in two cell
volumes of lysis buffer (50 mM Tris, 200 mM KCl, 20 mM imidazole, 5 mM MgCl 2, 20%
glycerol, pH 8.0). Cells were lysed using sonication, and centrifuged to collect
supernatant. S. pombe Pop2 was expressed with a His-tag, which allowed nickel resin
purification. Supernatant was incubated for 1.5 hours with nickel resin equilibrated with
lysis buffer. Nickel resin was washed 10 times with wash buffer (50 mM Tris, 200 mM
KCl, 20 mM imidazole, 5 mM MgCl2, 3 mM BME, pH 8.0) followed by 7 elutions with
elution buffer (50 mM Tris, 200 mM KCl, 250 mM imidazole, 5 mM MgCl2, 3 mM BME,
pH 8.0). Elutions were pooled, filtered, and allowed to dialyze with TEV protease (100:1
ratio) overnight at 4°C in dialysis buffer (50 mM Tris, 100 mM KCl, 5 mM MgCl2, 3 mM
BME, pH 8.0) to remove the His tag. TEV-cleaved protein was put back over nickel resin
to bind the TEV protease enzyme, and the purified protein sample was collected and
stored at -80°C.
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Enzymatic Assays – Reactions were carried out as described in Chapter 2.
Protein substrate concentrations (Npl3, histone H4 protein) were 0.5 μM. Peptide
substrate concentrations were 200 μM. Enzyme concentration (Hmt1) remained at 100
nM for all reactions. All other concentrations are as listed in Chapter 2.
Yeast Cell Growth and Lysate Preparation – The yeast strains used (wild type,
ΔPop2, and ΔHmt1) were generously provided by Dr. Michael C. Yu, Department of
Biological Sciences, University at Buffalo, New York. Yeast cells were grown in YEPD
media to an OD600 of 1.0, then washed with PBS and treated with various media
conditions for 2 hours: YEPD, YEP (no glucose added), or YEPD media with 200 nM
Rapamycin. Cells were harvested via centrifugation. Pellets were resuspended in
approximately 20 cell volumes of lysis buffer (PBS, 10 μg/mL RNase A, 1 mM EDTA, 1
mM PMSF), and sonicated in a Rosette cell to provide optimal cooling conditions while
thoroughly lysing the cells. Cell lysates were clarified with centrifugation, and
supernatants were collected.
Western Blot Analysis – Western transferring and blotting were performed
according to manufacturer’s instructions (BioRad) using a PVDF membrane. Antibodies
used were as follows: Rabbit polyclonal to beta actin – loading control (Abcam ab822750); Anti-asymmetric dimethyl arginine ASYM24 (Upstate Cell Signaling Solutions);
Mouse monoclonal to mono and dimethyl arginine (Abcam ab412-200). Western blots
were developed using Pierce Fast Western Blot Kit (Thermo Scientific) detection
reagents, and visualized with a Fuji LAS-3000 Lite imager.
Radioactive Gel Assay – Reactions were performed similarly to those mentioned
above. Sample time points were quenched in XT Sample Buffer (BioRad), and run on
Criterion XT Bis-Tris 10% Acrylamide Precast Gel according to manufacturer’s
instructions (BioRad). The gel was transferred to a PVDF membrane using standard
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Western blotting protocol. The membrane was sprayed with En3Hance Spray (Perkin
Elmer) and exposed to film. Film was developed and imaged using Fuji LAS-3000 Lite
imager.
Results and Discussion
As discussed in Chapter 2, full-length Pop2 from S. cerevisiae was shown to
inhibit the methylation of histone H4 protein by Hmt1 enzyme. However, due to low
expression and poor purification of the full-length Pop2, a truncation with a TEVcleavable His-tag was used for additional experiments. This construct included amino
acids 147-433, which is the RNase domain and the portion of the Pop2 sequence that is
conserved with the human hCaf1 protein.18 We hypothesized that the N-terminus of
Pop2 would not play a role in its regulation of PRMTs since hCaf1 does not contain this
domain. Indeed, radioactive assays demonstrated that the Pop2 (Δ1-146) construct
inhibits the methylation of histone H4 protein by Hmt1 in a concentration-dependent
manner (Figure 3-1). With increasing concentrations of Pop2 (Δ1-146), we observed a
linear decrease in overall rate of the reaction. With respect to histone H4 protein as a
substrate, Pop2 (Δ1-146) does appear to regulate methylation by Hmt1 similarly to
hCaf1.
The next step was investigating the effect of Pop2 on the methylation of other
substrates, both proteins and peptides. This would help us decipher the inhibitory
mechanism of Pop2, as well as its specificity as a regulator. Among other Hmt1
substrates tested were Npl3, a yeast hnRNP protein, and R3, a common 20-residue in
vitro peptide substrate used in PRMT enzymatic activity assays. However, the
methylation rate of neither of these substrates seemed to be significantly affected by the
presence of Pop2 (Figure 3-2). This suggested that Pop2 is able to specifically regulate
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Figure 3-1. Pop2 (Δ1-146) concentration-dependent inhibition of Hmt1-catalyzed
methylation of histone H4 protein substrate. (A) Quantified methylation at various
time points for reactions containing no Pop2 (■), 50 nM Pop2 (♦), 200 nM Pop2 (▲), 350
nM Pop2 (▼), and no substrate as the baseline control (●). (B) Reaction rates from A
plotted against concentration of Pop2 (Δ1-146), showing the linear decrease in reaction
rate with increasing concentrations of Pop2 (Δ1-146).

Figure 3-2. Full-length and truncated (Δ1-146) Pop2 inhibition assays of Hmt1catalyzed methylation of various substrates. (A) Methylation of Npl3 protein
substrate at various time points for reactions containing no Pop2 (■), and 100 nM fulllength Pop2. Reactions were initiated with either substrate (♦), or with enzyme (▲). No
substrate was used as the baseline control (●). (B) Similar to A, reaction time points with
R3 peptide substrate without Pop2 (■), or with 100 nM Pop2 (Δ1-146) (♦), and the
absence of substrate as the baseline control (●).
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the methylation of histone H4 protein substrate and possibly other substrates, while
leaving others unaffected.
In order to investigate the conservation of the regulatory function exhibited by
Pop2 among yeast species, activity assays with histone H4 protein as substrate were
also performed with Pop2 from Schizosaccharomyces pombe (Figure 3-3). We
hypothesized that Pop2 from this yeast species would also exhibit a similar regulatory
effect. As expected, there was a significant drop in methylation of histone H4 protein
substrate in the presence of S. pombe Pop2 in addition to full-length S. cerevisiae Pop2.
Not only does this result suggest an evolutionarily conserved function for Pop2 in the
regulation of Hmt1-catalyzed methylation in yeast, it also reaffirms the evolutionary
relationship between hCaf1 and both yeast species of Pop2 in regulating arginine
methylation of certain substrates. This implies a conservation of an important regulatory
mechanism throughout eukaryotic evolution.

Figure 3-3. Full-Length Pop2 from S. cerevisiae and S. pombe inhibition assays of
Hmt1-catalyzed methylation of histone H4 protein substrate. Methylation of histone
H4 protein substrate at various time points for reactions containing no Pop2 (■), 100 nM
full-length His-tagged S. cerevisiae Pop2 (♦), or 100 nM full-length S. pombe Pop2 (▲). A
reaction with no substrate present was used as the baseline control (●).
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Our next goal was to explore the extent of the effects of Pop2 on other substrates
in a broader context. In order to accomplish this, several experiments were done with
whole yeast cell lysates. The first experiment involved reactions with hypomethylated
yeast cell lysate obtained from ΔHmt1 yeast cells. The lysate was used in reactions with
[3H]-SAM in the presence and absence of added full-length His-tagged Pop2, followed
by western transfer and exposure to film to visualize protein bands that had incorporated
tritium. In this experiment, the presence of full-length Pop2 demonstrated an altered
pattern of methylation of multiple yeast protein substrates, suggesting a broader scope
of influence for Pop2 in PRMT regulation (Figure 3-4 A).

Figure 3-4. Pop2 from S. cerevisiae and its effects on yeast cell lysate methylation.
(A) Autoradiograph of reactions with hypomethylated yeast cell lysate from ΔHmt1 yeast
cells +/- Pop2 in the presence of [3H]-SAM and exogenous Hmt1. Time points were
taken at 20 and 60 minutes. –Sub: no yeast cell lysate (control). –Pop2: no Pop2 added.
+Pop2: 100 nM Pop2 added. (B) Western blot of wild type (WT) and ΔPop2 (ΔP) yeast
cells grown in various media: regular media (YEPD), no glucose (YEP), and YEPD +200
nM Rapamycin (Rap). Top panel: ADMA antibody. Middle panel: MMA/ADMA antibody.
Bottom panel: Beta-actin loading control antibody.

This finding was further validated in another experiment involving wild type and
ΔPop2 yeast strains grown in various media conditions: normal media (YEPD), glucose
deprived (YEP), and YEPD media with 200 nM Rapamycin. Rapamycin is a drug
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commonly used to imitate a cell starvation response. These conditions were chosen
because of studies that reported the phosphorylation of Pop2 under glucose limiting
conditions, and altered Hmt1 activity under similar starvation or Rapamycin-treated
conditions.9,19 We were interested in the effects these conditions would have on Pop2
and whether they would alter its regulatory function. Western blot analysis was used to
compare the two different yeast strains from each type of media, and demonstrated that
the absence of Pop2 led to an increase in the amount of methylation in all tested media
conditions, including glucose deprivation (Figure 3-4 B). This again suggested that Pop2
may regulate the methylation of many substrates beyond just histone H4 protein, and
could be involved in a variety of regulatory pathways.
The next major question that needed to be addressed was how Pop2 was able to
accomplish its regulatory effect on arginine methylation. Previous studies have shown
Hmt1 and Pop2 to associate, and PRMT1 and hCaf1 have been shown to colocalize.14,16
Our first hypothesis was that Pop2 and Hmt1 could be directly interacting. However,
after numerous attempts to detect a complex between these two proteins using crosslinking, pull-downs, and immunoprecipitation experiments, no complex was observed
(pull-down in Figure 3-5 A, other data not shown). A transient complex could have
formed with weak interactions, but we could not detect or isolate it. The next hypothesis
tested was that Pop2 could be interacting with the substrate instead of the enzyme, and
is thus able to accomplish its selective inhibition. Control pull-downs with Pop2 (Δ1-146)
and histone H4 protein alone revealed that histone H4 protein nonspecifically binds to
nickel resin very tightly (data not shown). We were thus able to use histone H4 protein to
pull down TEV-cleaved Pop2 (Δ1-146), which was no longer capable of binding to nickel
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resin. These pull-downs using purified histone H4 protein and Pop2 (Δ1-146) suggested
a direct interaction as the two proteins eluted together (Figure 3-5 B).

Figure 3-5. Nickel resin pull-downs with Pop2 (Δ1-146). (A) Pop2 (Δ1-146) and Histagged Hmt1 were combined, allowed to incubate, and then pulled down using nickel
resin. No interaction was apparent between Hmt1 and Pop2 (Δ1-146). (B) TEV-cleaved
Pop2 (Δ1-146) and histone H4 protein were incubated together, followed by nickel resin
pull-downs utilizing the nonspecific binding of histone H4 protein to nickel resin. Both
proteins eluted together, suggesting a direct interaction. 

This interaction between Pop2 (Δ1-146) and histone H4 protein was an exciting
discovery because it suggests a novel protein-protein interaction that has not previously
been postulated. It was known that Pop2 and hCaf1 associated with their respective
PRMTs, but their association was not known to be via direct interactions or not. This
novel interaction between Pop2 and histone H4 protein suggests that histone H4 (and
possibly other proteins as well) could potentially act as a bridging molecule that causes
Pop2 and Hmt1 to be associated in turn.
In order to identify the specific surface of Pop2 (Δ1-146) responsible for its
interactions with histone H4 protein, several Pop2 (Δ1-146) variants were designed
based on a solvent-exposed helix from the crystal structure (Figure 3-6).18 This particular
helix was hypothesized as a potential site of interaction for several reasons. First, some
of the other conserved surfaces of Pop2 are already known to interact with other

49
proteins, such as Ccr4 and Not1 of the Ccr4-Not complex via hydrophobic interactions
(Figure 3-6).20,21 These surfaces were eliminated as they were less likely to be
responsible for the novel interaction with histone H4 protein. Second, the outward-facing
residues of this helix were conserved with S. pombe Pop2 and with hCaf1. If there is a
specific function conserved among these proteins, then it usually follows that there are
structural and sequential characteristics that are also conserved. Based on this
reasoning, we hypothesized that there must be some commonality between these three
Pop2 homologs which allowed them to achieve their regulatory function. We further
hypothesized that the selected helix or the region surrounding it could be part of that
commonality responsible for methylation inhibition.

Figure 3-6. Crystal structure of S. cerevisiae Pop2 (Δ1-146). Backbone of Pop2 is
shown in blue. Locations of interactions with two other members of the Ccr4-Not
complex, Ccr4 and Not1, are labeled as shown. Ccr4 is located diagonally down and to
the left. Not1 is located to the right and towards the back of the structure. The residues
chosen for mutagenesis are labeled in orange with side-chains shown as sticks. All three
residues shown in orange were mutated to alanine.
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Three outward-facing conserved residues on the selected helix of Pop2 (Δ1-146)
were chosen for mutagenesis: E260, E263, and K267 (Figure 3-6). Each of these
residues were mutated to alanine, and the wild type Pop2 (Δ1-146) truncation was used
as the template.
Inhibition assays were performed with wild type Pop2 (Δ1-146), and each of its
variants (E260A, E263A, and K267A), similar to the assays discussed earlier (Figure 37). Both E260A and E263A showed similar inhibitory effects to wild type Pop2 (Δ1-146).
However, the K267A variant had a decreased ability to inhibit methylation. This led us to
hypothesize that K267 may be an important residue for interacting with histone H4
protein. Additional experiments will further probe the precise surfaces of Pop2 that are
involved in this regulatory protein-protein interaction.

Figure 3-7. Methylation assays with Hmt1 and histone H4 protein substrate in the
presence and absence of Pop2 (Δ1-146) wild type and mutants. (A) Hmt1 reactions
with [3H]-SAM similar to those previously described. Reactions with no Pop2 (Δ1-146)
(●), wild type (■), E260A (▲), E263A (▼), and K267A (♦) time points are shown. (B)
Methylation reaction rates from panel A plotted for each type of Pop2 (Δ1-146): wild type
(WT), and the three variants.
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The next step was to see if the decreased inhibitory capacity of Pop2 (Δ1-146)
K267A was due to a hindered ability to interact with histone H4 protein. In order to
assess this, nickel resin pull-downs were performed with histone H4 protein similarly to
those performed with wild type Pop2 (Δ1-146) (Figure 3-8). As the figure shows, Pop2
(Δ1-146) K267A eluted with histone H4 protein, suggesting that the two proteins are still
interacting. That being said, this experiment was a more qualitative method of examining
the interaction between these two proteins. Future experiments using more quantitative
techniques can investigate more slight alterations in the amounts of interacting protein to
test whether Pop2 (Δ1-146) K267A has a lowered affinity for histone H4 protein.

Figure 3-8. Nickel resin pull-down with Pop2 (Δ1-146) K267A. TEV-cleaved Pop2
(Δ1-146) K267A and histone H4 protein were incubated together, followed by nickel
resin pull-downs utilizing the nonspecific binding of histone H4 protein to nickel resin. 

Conclusion
We have demonstrated concentration-dependent methylation inhibition of histone
H4 protein substrate by Pop2 (Δ1-146) protein from S. cerevisiae, and show this
regulatory effect to be conserved in S. pombe. We also present data that shows an
altered methylation pattern of many other yeast substrates in vivo and in vitro in the
presence and absence of Pop2.
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Based on a novel interaction discovered between Pop2 (Δ1-146) and histone H4
protein, we propose a substrate-sequestering mechanism that accomplishes methylation
inhibition of histone H4 protein substrate. This was a fascinating and rather unexpected
discovery, since many regulators bind to the enzyme rather than the substrate to
regulate catalytic activity. A diminished ability to inhibit methylation by the K267A variant
of Pop2 (Δ1-146) led us to hypothesize that the region around this residue may be
involved. This finding could have powerful significance if the same regulatory
mechanism exists in humans with hCaf1, and if the interaction with histone H4 can be
specifically altered or modified for medicinal applications.
This and future experiments will further expound upon the details of how PRMTs
are regulated in vivo in yeast and mammals and how they can be pharmaceutically
regulated. Given the wide variety of arginine methylation substrates, artificial regulation
of PRMT activity toward specific substrates is an extremely difficult challenge. However,
with these findings and other future work, there is potential for the design of substratespecific regulators of PRMTs, which would allow selective methylation inhibition of
certain PRMT targets while leaving other substrates unaffected. Accomplishing this goal
of selective PRMT regulation could have profound implications in the treatment of the
many human diseases in which PRMTs have been implicated so far.
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CHAPTER 4
SUMMARY AND FUTURE WORK
Review
Eukaryotes have a multitude of cellular pathways and processes that must be
maintained for survival, from the simpler organisms like unicellular yeast to the much
more complex human. In order to accomplish such a diverse set of functions, the
proteome has the capability to be modified and expanded through post translational
modifications (PTMs). One of these critical PTM’s is arginine methylation, which is
catalyzed by the protein arginine methyltransferase (PRMT) family of enzymes. The
study of PRMTs has gained momentum in recent years as these enzymes and their
many substrates have been discovered to be pervasive and vital in numerous cellular
processes (Chapter 1). Some PRMTs have also been implicated in several human
diseases, further emphasizing the urgency in understanding how PRMTs function and
are regulated within the cell (Chapter 1). PRMT1 and Hmt1, the predominant PRMTs in
mammals and yeast (Saccharomyces cerevisiae), respectively, have been two of the
main focuses in this area of study.
In order to gain further insight into how PRMTs are regulated, we have
expressed and purified full-length and truncated (Δ1-146) constructs of the yeast Pop2
protein, a potential regulator of Hmt1 (Chapter 2). We have also studied its regulatory
effects on several Hmt1 substrates, including histone H4 protein, and have shown Pop2
(Δ1-146) to be a concentration-dependent inhibitor of Hmt1-catalyzed methylation of this
substrate (Chapter 3). We have also demonstrated that full-length Pop2 may regulate
the methylation of many other substrates in vivo (Chapter 3). Additionally, we present
data that supports a substrate-sequestering mechanism for methylation inhibition, and
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suggest a region of Pop2 (Δ1-146) that may contribute to an important protein-protein
interaction (Chapter 3). For each of these projects, a brief summary is provided below,
followed by future work and directions.
Expression and Purification of Pop2
Pop2 was selected as a potential regulator of Hmt1 as a result of experimental
evidence demonstrating that hCaf1, the human homolog of Pop2, was a regulator of
PRMT1.1 hCaf1 was shown to regulate the methylation of several substrates by PRMT1,
including histone H4 protein. Based on these data, we hypothesized that Pop2, like
hCaf1, would regulate Hmt1-catalyzed methylation of histone H4 protein, and possibly
other substrates. This chapter focused on the expression and purification of various
constructs of Pop2. Although the original full-length His-tagged Pop2 showed inhibition
of histone H4 protein methylation by Hmt1, its expression was rather low, and purity was
in need of improvement.
The final and most successful construct of Pop2 was a truncated (Δ1-146)
construct with a TEV-cleavable His-tag. Expression and overall purity of this construct
both greatly increased. This specific truncation was created for two primary reasons.
First, it is the same construct used by the group that solved the crystal structure of Pop2,
and includes the RNase domain of Pop2.2 This allowed us to use conserved structural
characteristics in exploring the regulatory mechanism of Pop2 (Chapter 3). Second, this
portion of the Pop2 protein is the section of Pop2 that is conserved with human hCaf1
and S. pombe Pop2 sequences.2,3 This suggested that this truncation of Pop2 included
the relevant part of the protein that is responsible for the function of regulating
methylation.
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Despite the advantages of the truncated (Δ1-146) construct of Pop2, several
steps during the purification process proved problematic. The construct was
exceptionally susceptible to protein precipitation during and after TEV-cleaving, which
resulted in loss of most or all of the Pop2 (Δ1-146) protein during purification. However,
by raising the temperature from 4°C to 16°C during these steps, the precipitation issues
were immediately resolved. We concluded that this truncated (Δ1-146) construct of the
Pop2 protein becomes temperature sensitive following TEV-cleavage of the His-tag.
Once this hurdle was overcome, the Pop2 (Δ1-146) construct became stable in solution
and could be used for further experimentation.
Regulation of Hmt1-Catalyzed Methylation by Pop2
In order to examine the effect of Pop2 on the methylation by Hmt1, activity
assays were first performed with histone H4 protein substrate with [3H]-S-adenosyl-Lmethionine (SAM) as a tracer. Addition of Pop2 (Δ1-146) resulted in decreased rates of
methylation in a concentration-dependent manner. We concluded that Pop2 (Δ1-146)
mimics hCaf1 in inhibiting the methylation of histone H4 protein, confirming this
homologous function. Interestingly, there was no inhibition observed in the methylation
of two other Hmt1 substrates, Npl3 and R3 peptide, in the presence of full-length Pop2.
To confirm that histone H4 protein methylation was in fact being inhibited by
Pop2, S. pombe Pop2 was also added to methylation reactions with histone H4 protein.
The inhibitory effect was comparable to that observed with Pop2 from S. cerevisiae. This
suggested that the regulatory function of Pop2 is conserved among yeast species as
well as being conserved in humans via hCaf1.
To explore the scope of Pop2 and its effects on the methylation of other
substrates, several in vivo and in vitro experiments were conducted utilizing different
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yeast strains. Using [3H]-SAM and western blot analysis, results showed altered patterns
of methylation in the presence and absence of Pop2. The first experiment involved
hypomethylated yeast cell lysate from ΔHmt1 cells in reactions with exogenous Hmt1 in
the presence and absence of additional full-length Pop2. The results demonstrated an
overall decrease in methylation of substrates after 20 minutes in the presence of
additional full-length Pop2. The second experiment examined the methylation
differences in wild type and ΔPop2 yeast cells in vivo. Western blot analysis of cell
lysates from these growths showed an overall increase in arginine methylation (both
ADMA and MMA) from the ΔPop2 yeast cells when compared to wild type, suggesting
that the loss of Pop2 allowed methylation of substrates that otherwise would not occur,
or would usually occur at a lower rate.
Discovering the mechanism that Pop2 employs to accomplish the observed
regulation of arginine methylation was the goal of the next set of experiments. Previous
studies have shown that hCaf1 and PRMT1 colocalize in vivo, and pull-downs from
yeast cell lysates have shown an interaction between Hmt1 and Pop2.1,4 Based on these
data, we hypothesized that Pop2 could be directly interacting with Hmt1, preventing it
from methylating its substrates. However, several pull-down, cross-linking, and
immunoprecipitation experiments have yielded no evidence of such an interaction in
vitro.
Finally, a pull-down using only purified histone H4 protein and Pop2 (Δ1-146)
showed a direct interaction, suggesting that Pop2 inhibits methylation by the
sequestration of certain substrates. This type of mechanism agrees with the apparent
lack of methylation inhibition by Pop2 of the other substrates tested. Despite previous
studies that have alluded to a direct interaction between PRMTs and Pop2/hCaf1, it
appears that the two proteins may not directly interact at all. The novel interaction

59
between Pop2 (Δ1-146) and histone H4 protein suggests that there could be one or
more bridging molecules that result in associations of PRMTs with Pop2/hCaf1, and
possibly a three-way complex between PRMT, substrate, and Pop2.
To further explore how Pop2 inhibits methylation, we employed site directed
mutagenesis on a carefully targeted surface of Pop2 (Δ1-146) that we hypothesized was
involved in its interaction with histone H4 protein. Based on the crystal structure of Pop2,
we chose three residues located on an alpha helix that pointed out into solution, and
were on a surface that was not currently known to interact with other proteins.2,5,6 We
mutated E260, E263, and K267 to alanines, and performed methylation activity assays
with them along with wild type Pop2 (Δ1-146). Although E260A and E263A showed
similar results to wild type Pop2 (Δ1-146), the K267A variant demonstrated a decreased
ability to inhibit the methylation of histone H4 protein by Hmt1. This suggested that K267
and possibly a region proximal to it is involved in an important interaction responsible for
the regulation of arginine methylation.
Summary and Future Work
This thesis has contributed to the foundation of knowledge concerning the
regulation of PRMTs, an area that is currently being investigated but remains poorly
understood in this field. With the implication of PRMTs and dysregulated arginine
methylation in various human disease states, selective regulation of PRMTs is becoming
an appealing target for pharmaceuticals.7 However, this can be more challenging than it
seems when inhibiting one PRMT can have many widespread consequences in addition
to the one targeted.
Here, we have shown selective methylation inhibition of a substrate via a novel
protein-protein interaction that leaves some substrates unaffected. Further experiments
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are currently needed to fully understand the effects of Pop2 on arginine methylation.
However, progress is currently bottle-necked by inconsistent activity of recombinant
Hmt1 from various purifications. Once Hmt1 activity is stabilized, additional experiments
and methylation rate data can expound upon and define additional details of how Pop2
inhibits arginine methylation.
Future experiments could include optimizing the immunoprecipitation and crosslinking experiments described below that were unable to yield any conclusive results.
Using various antibodies specific to histone H4, Hmt1, and Pop2 in such
immunoprecipitation experiments could yield some exciting results as each is used in
turn to pull down the other proteins. Additional work could also include similar pull-downs
as well as methylation activity assays using histone H4 protein that is monomethylated
at arginine 3. This would explore the questions of whether Pop2 is able to differentiate
between and associate with this substrate compared to unmodified histone H4 protein,
and whether the ability of Pop2 to regulate methylation is altered under these
circumstances.
Various mutations and truncations of Pop2 could be created and used to further
define and clarify the regions of Pop2 that are responsible for its inhibitory function.
Methylation activity assays with various constructs could reveal and narrow down the
smallest region of Pop2 required for methylation inhibition. Perhaps a stable complex
between a construct of Pop2 and its interacting partner(s) could be isolated and purified
for crystal structure determination. This would shed a great deal of light on the precise
regions of Pop2 that are important for its interactions, as well as discovering the regions
of histone H4 and Hmt1 that could also be involved.
Additionally, there are other substrates of Hmt1 besides histone H4 that could be
influenced by interaction with Pop2. Methylation activity assays with proteins that are
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predicted to interact with Pop2 could identify which of these substrates are regulated in a
similar manner to histone H4. These proteins could also be used in pull-down
experiments as described above to further define the mechanism employed by Pop2. All
of these experiments could be done using the Pop2 protein from S. pombe in confirming
these effects of Pop2 in another yeast species, and suggesting an evolutionarily
conserved novel function for this protein.
Future work will explore the details of how specific regulation of arginine
methylation is accomplished, and exploit that information in designing pharmaceuticals
that can specifically target and modulate dysregulated PRMT activity without disturbing
the essential roles that PRMTs play in cellular physiology. Future research will continue
to uncover various ways that PRMTs are regulated, and the mechanisms of how their
activity can be modified to treat and even cure human diseases.
Additional Experiments
Several experiments were performed when attempting to detect complexes
between histone H4 protein, Pop2 (Δ1-146), and Hmt1. However, due to technical
obstacles in optimizing the protocols, these experiments were inconclusive. For the sake
of completeness and thoroughness, the protocols for those experiments are included
below.
Cross-Linking Experiments – Equimolar amounts (0.3 or 0.5 μM) of histone H4
protein, Hmt1, and Pop2 (Δ1-146) were incubated together in 100 μL of PBS pH 7.5 for
approximately 20 minutes. Gluteraldehyde (Sigma) was added at final concentrations of
0.025% or 0.1%, and the samples incubated at room temperature for 5 minutes. The
cross-linking reactions were quenched with 10 μL of 1 M Tris-HCl pH 8.0. Samples were
resolved by SDS-PAGE, and then transferred to a PVDF membrane. The western
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membrane was then stained with Ponceau S Solution (Sigma) to visualize all proteins,
followed by rinsing to destain. Western blots were performed on the membrane using
antibodies specific to each protein: Anti-CNOT7 polyclonal antibody to detect Pop2
(Pierce, PA5-31139), anti-histone H4 (H-97) (Santa Cruz sc-10810), and anti-Hmt1
(generously provided by Dr. Michael C. Yu, Department of Biological Sciences,
University at Buffalo, New York). Complexes corresponding to the correct molecular
weights were not detected (Figure 4-1). However, with optimization of this protocol,
viable results may be possible.

Figure 4-1. Western blots of cross-linking Hmt1, H4 protein, and Pop2 (Δ1-146).
Lanes 1-5: Anti-His western blot detecting His-tagged Hmt1. 1 = Hmt1 only. 2 = Hmt1
and H4. 3 = Hmt1 and Pop2. 4 = Hmt1, Pop2, and H4. 5 = Hmt1, Pop2, and H4 with
0.1% gluteraldehyde. Lanes 6-9: Anti-H4 western blot. 6 = H4 only. 7 = H4 and Pop2.
8 = H4 and Hmt1. 9 = H4, Pop2, and Hmt1. Lanes 10-13: Anti-CNOT7 western blot
detecting Pop2. 10 = Pop2 only. 11 = Pop2 and H4. 12 = Pop2 and Hmt1. 13 = Pop2,
H4, and Hmt1. All other gluteraldehyde concentrations were 0.025%. Approximate
molecular weights: Hmt1 42 kDa; Pop2 33 kDa; histone H4 protein 11 kDa.
Approximate molecular weights of potential complexes: Hmt1 and Pop2 75 kDa;
Hmt1 and histone H4 53 kDa; Pop2 and histone H4 44 kDa; Hmt1, Pop2, histone H4
86 kDa; Hmt1 dimer 84 kDa; Hmt1 dimer and histone H4 95 kDa; Hmt1 dimer and
Pop2 117 kDa; Hmt1 dimer, histone H4, and Pop2 128 kDa; Hmt1 trimer 126 kDa;
Hmt1 tetramer 168 kDa.
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Immunoprecipitations – Protein A sepharose (Sigma) was resuspended in buffer
A (20 mM phosphate, 150 mM NaCl, pH 8.0) and allowed to swell for 30 minutes,
followed by equilibration with buffer A. The sepharose was allowed to incubate overnight
with anti-His antibody (Santa Cruz sc-8036) and rabbit anti-mouse secondary antibody
(Open Biosystems) at 4°C with agitation. The secondary antibody was used because
mouse IgG1 antibodies, such as the anti-His antibody used in this experiment, do not
have a very high affinity for protein A sepharose. The secondary antibody allows more of
the primary antibody to bind to the sepharose. His-tagged Hmt1 was then added to the
sepharose solution (final concentration 10 μM) and allowed to incubate at 4°C with
agitation for 4 hours. The sepharose was then washed twice with PBS by spinning down
at 1,000xg at 4°C for 1 min each time. Histone H4 protein was then added (final
concentration 6 μM) and allowed to incubate for 15 minutes, followed by the addition of
TEV-cleaved Pop2 (Δ1-146) (final concentration also 6 μM). The solution then incubated
2 hours at 4°C with agitation. Following incubation, the solution was centrifuged
(1,000xg, 1 min, 4°C) and again washed 3 times with PBS. Samples were eluted by
adding SDS sample buffer, boiling 5 minutes, centrifuging, and pipetting off the
supernatant. Samples were resolved by SDS-PAGE, and bands were visualized using
SYPRO Ruby Protein Gel Stain (Sigma). Obstacles with this experiment included
difficulty binding the antibodies to the sepharose, and control experiments demonstrated
that histone H4 protein nonspecifically binds to Protein A Sepharose. Future work in
optimizing these protocols could work around these issues and present valuable data on
the potential interactions taking place between Hmt1, Pop2, and histone H4 protein.
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